THE DRGS SUB-GROUP PROGRAM ANNOUNCED THE LAUNCH OF DRUG REFORM IN 30 CITIES.

Pharmaceutical Network June 22 - Health insurance payment reform speed up, public hospital revenue has changed, the future of pharmaceutical companies will be forced to make changes in the marketing model, a large number of small and medium-sized pharmaceutical companies face elimination.On June 18, the Subdivision Group (CHS-DRG) Sub-Group (VERSION 1.0) of The Medical Diagnosis Of Health Care Diseases (VERSION 1.0) was publishedThe document is also seen by the industry as a companion to the NHS's push for THE REFORM of DRGs, accelerating changes to the revenue mechanism of publichospitals, which will affect every link in the entire industrial chain in the future.DRGs (Diagnosis Related Groups), the grouping of disease diagnosis-related, refers to the use of information from discharged patients, taking into account the patient's main diagnosis and treatment methods, combined with individual signs such as age, complications and accompanying disease, the complexity and cost of the disease is divided into the same (DRGs) group, so that different intensity and complexity of medical services have an objective basis for comparison and evaluation of the cost-effective treatment and diagnosis.It is understood that the NATIONAL Health Insurance Bureau announced the CHS-DRG sub-group is the "National Health Care DRG (CHS-DRG) sub-programme" 376 sets of core DRG (ADRG) further refinement, is the basic unit of DRGs payment, a total of 618 groups.According to the overall idea of "three-step walk" of THE reform of DRGs, 30 pilot cities nationwide this year will enter the simulation operation stage, and 2021 will move towards the actual payment stage.industry generally believethat that the introduction of this "sub-group program", no doubt let all DRGs simulation of the pilot city will have to rely on, which will completely change the revenue model of medical institutions, pharmaceutical companies will smell the wind, the industry shuffle will follow.By the end of August, 30
pilot cities will be fully enrolled in the DRGsmodel
in October 2019, the State Health Insurance Administration identified 30 cities, including Beijing, Tianjin and Hebei Province, as the pilot cities for disease diagnosis-related sub-groups (DRGs), which also kicked off the reform of drug use in public hospitals.As an important part of the reform of medical insurance payment method, DRGs is the driving force of the unreasonable growth of medical expenses by converting drug revenue into the cost of medical institutions, through the assessment means of total advance payment and balance retention.It is understood that the National Health Insurance Administration announced the "sub-group program", is in accordance with the update of the national medical security information business coding standards for the core disease diagnosis related sub-programs have been fine-tunedIn accordance with the grouping principles of "clinical process similarity" and "resource consumption similarity", the core disease diagnosis-related group (ADRG) was grouped into 167 surgical operation groups, 22 non-operating room operation groups and 187 internal medicine diagnostic groups, with a total of 376 core disease diagnosis-related groups, covering all critical short-term (within 60 days) hospitalization cases.The Sub-group Programme requires that the pilot cities submit their assessment reports to the DRGs Paid National Pilot Technical Steering Group by August 31, and that the simulation run phase be carried out only after review and approvalThis means that by the end of this year, 30 pilot cities of medical institutions into the DRGs simulation operation phase, the hospital market pattern is about to change.It is generally believed in the industry that after the introduction of DRGs, all medical institutions will raise the price of medical services, reduce the income ratio ofdrug, consumables, and achieve the goal of improving the quality of medical services But this is a huge challenge for small and medium-sized hospitals at the county level Some analysts pointed out that the number of hospital stays will be strictly controlled by DRGs, resulting in a medical facility empty bed rate will be improved, which would have a direct impact on the original insufficient passenger flow of county hospitals, will directly affect its operating income .　　Agents are facing the elimination of 4000 pharmaceutical companies to adjust the idea of adjusting the layout
with the promotion of DRGs reform, the adjustment of the income structure of medical institutions, which will directly affect the future development direction of China's 4000 pharmaceutical companies In fact, medical institutions in the past through large prescriptions, excessive medical treatment for the hospital benefits, but under the reform mechanism of DRGs, can only save the health insurance balance as the operating income of medical institutions, which will undoubtedly be a huge change in the development of medical industry .　　On the other side of the coin is that traditional drug marketing, long driven by high drug pricing and channel space, will come to an end More crucially, when the sales space of pharmaceutical manufacturers and medical institutions is compressed, there will be a large number of agents face elimination in the future .　　Some analysts pointed out that there are currently 30 pilot cities to promote DRGs reform, which involves a lot of first-line key markets, so pharmaceutical companies must change sales ideas, step up strategic layout .　　The biggest change in DRGs reform is to shift the sales of pharmaceutical companies from sales of only a single product to a single product This means that pharmaceutical companies not only need a single sales data for drugs, but also understand the characteristics of all products in the relevant treatment field, and whether they can be sold with their own product portfolio .　　It is generally accepted in the industry that the implementation of the DRGs policy will change the drug use behavior of medical institutions, reduce the proportion of unreasonable drug use, and promote pharmaceutical companies to enhance the value of products, in order to achieve the goal of sustainable medical insurance costs In the short term, a number of domestic pharmaceutical companies producing therapeutic drugs will usher in a good opportunity for development In the long run, excellent product quality and obvious cost advantages, strong capital and strong research and development capabilities of enterprises , will eventually win in the market competition .